Competitor Analysis: Antibody-Drug Conjugates (ADC)
Product description
The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The emerging therapeutic class of antibody-drug conjugates (ADC) is coming of age. Two approved and marketed ADC drugs utilizing each one of the two major technologies (auristatin and maytansin derivatives) have paved the way for a total of further 33 ADCs in clinical studies and further six ADCs in IND enabling studies. Adcetris posted US sales of US$ 138 mln in 2012 and with the start of marketing of Kadcyla, sales of this therapeutic class are expected to reach blockbuster size. New linker and toxic payload technologies are being developed and the first representative ADCs from the new technologies are approaching clinical proof of concept testing.
The report includes a compilation of currently active projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology. In addition, the report lists company-specific R&D pipelines of antibody-drug conjugates. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The emerging therapeutic class of antibody-drug conjugates (ADC) is coming of age. Two approved and marketed ADC drugs utilizing each one of the two major technologies (auristatin and maytansin derivatives) have paved the way for a total of further 33 ADCs in clinical studies and further six ADCs in IND enabling studies. Adcetris posted US sales of US$ 138 mln in 2012 and with the start of marketing of Kadcyla, sales of this therapeutic class are expected to reach blockbuster size. New linker and toxic payload technologies are being developed and the first representative ADCs from the new technologies are approaching clinical proof of concept testing.
The report includes a compilation of currently active projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology. In addition, the report lists company-specific R&D pipelines of antibody-drug conjugates. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
- Adcetris Pipeline
- Antibody-Drug Conjugates with Auristatin Derivatives
- Antibody-Drug Conjugates with Pyrrolobenzodiazepine (PBD) Derivatives
- Kadcyla Pipeline
- Antibody-Drug Conjugates with Maytansinoid Derivatives
- Antibody-Drug Conjugates with Irinotecan Derivatives
- Antibody-Drug Conjugates with Doxorubicin
- Antibody-Drug Conjugates with Calicheamicin Derivatives
- Antibody-Drug Conjugates with Duocarmycin Derivative
- Antibody-Drug Conjugates with Various Drugs
- Antibody-Drug Conjugates with Not Disclosed Drugs
- Other Immunoconjugates
- Antibody-Drug Conjugates: R&D Collaboration Agreements
- Antibody-Drug Conjugates: Licensing Agreements About La Merie
- Corporate ADC R&D Pipelines
